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Abstract: This research aimed to evaluate the expression and clinical implication of autotaxin
(ATX)-lysophosphatidate (LPA) signaling-related proteins in breast cancer with adipose stroma.
To this end, a tissue microarray (TMA) was constructed from 137 breast cancer tissues with adipose
stroma and 329 breast cancer tissues with non-adipose stroma (inflammatory stroma: n = 81, 24.6%;
fibrous stroma: n = 246, 75.4%). Immunohistochemical staining for ATX-LPA signaling-related
proteins (ATX, LPA1, LPA2, and LPA3) was performed on the TMA. The results showed that LPA2 in
tumor cells and LPA3 in stromal cells were highly expressed in breast cancer with adipose stroma and
breast cancer with adipose and inflammatory stroma, respectively. Stromal LPA1 positivity (p = 0.017)
and stromal LPA3 positivity (p = 0.004) were higher in breast cancer with adipose stroma containing
CD68-positive crown-like structures (CLS). Stromal ATX positivity (p = 0.010) and stromal LPA3
positivity (p = 0.009) were higher in breast cancer with adipose tissue containing CD163-positive CLS.
In breast cancer with adipose stroma, the number of CD163-positive macrophages was greater with
stromal ATX positivity (p = 0.003), and the number of CD68-positive and CD163-positive macrophages
were greater in cases with stromal LPA3 positivity. In conclusion, ATX-LPA signaling-related proteins
are highly expressed in breast cancer with adipose stroma, with associated macrophage infiltration.
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1. Introduction
Autotaxin (ATX) is a glycoprotein encoded by the ENPP2 gene located on chromosome
8 [1]. Identical to lysophospholipase D, ATX plays a role in the synthesis of the bioactive lipid
mediator lysophosphatidate (LPA) from lysophosphatidylcholine (LPC). LPA binds to LPA receptors;
activates phospholipase C and the MAPK, PI3K, and PhoA pathways; and is involved in various
cellular processes [2,3]. LPA receptors are G-protein coupled receptors, and at least six LPA
receptors (LPA1-LPA6) have been identified. LPA1-LPA3 belong to EDG family (LPA1-EDG2,
LPA2-EDG4, LPA3-EDG7), and LPA4-LPA6 have a similar structure to the P2Y nucleotide receptor [4].
The ATX-LPA signaling axis is closely related to tumor biology, including tumor formation,
progression, and metastasis [5,6]. ATX is generated from platelets, endothelial cells, fibroblasts,
and adipocytes [7–10], and specifically, ATX from adipocytes has an impact on plasma LPA level [11].
Thus, adipocytes could be an important origin of ATX in tumors. Breast cancer is a human cancer that
has adipocyte-rich stroma. Adipose tissue comprises 56% of non-lactating breast [12] tissue, and 35%
of lactating breast tissue [13]. ATX-LPA signaling has been reported to be involved in angiogenesis,
tumor cell invasion, and migration in breast cancer [14].
Therefore, breast cancer with adipose stroma may differ in the expression of ATX-LPA
signaling-related proteins, and this possibility has not been investigated thoroughly. In this study,
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we evaluated the expression and clinical implications of ATX-LPA signaling-related proteins in breast
cancer with adipose stroma.
2. Materials and Methods
2.1. Patient Selection and Histologic Evaluation
A total of 137 breast cancer with more than 50% adipose stroma were collected from data files of
the Department of Pathology of Severance Hospital, Seoul, Korea. For comparison, 329 cases of breast
cancer with non-adipose stroma were included in the study. Only patients with a diagnosis of invasive
ductal carcinoma were included. All slides were reviewed after collection and pathologic diagnoses
were confirmed by two pathologists (Ja Seung Koo and Yoon Jin Cha). The histological grade was
assessed using the Nottingham grading system [15].
For stroma, the boundaries of the invasive tumor were identified and stroma inside them was
evaluated. If more than 50% of stroma was adipose tissue, then it considered as breast cancer with
adipose stroma. Cases with less than 50% of adipose stroma were divided into two subgroups according
to the type of stroma: inflammatory stroma and fibrous stroma. Cases having more than 50% of
stromal tumor infiltrating lymphocytes (TILs) were defined as breast cancer with inflammatory stroma.
The remainder were separately defined as breast cancer with fibrous stroma. Evaluation of stromal
TIL were according to the guideline of TIL working group [16].
2.2. Tissue Microarray (TMA)
A representative area showing tumor and tumor stroma was selected on a hematoxylin and eosin
(H&E)-stained slide, and the corresponding spot was marked on the surface of a paraffin block. Using
a biopsy needle, the selected area was punched out, and a 3-mm tissue core was transferred to a
6 × 5 recipient block. Two cores of invasive tumor tissue were extracted to minimize extraction bias.
Each tissue core was assigned a unique TMA location number that was linked to a database containing
other clinicopathologic data. Cases showed different tumor stromal nature after multiple sections of
TMA block were excluded.
2.3. Immunohistochemistry
The antibodies used for immunohistochemistry (IHC) in this study are shown in Table 1. Tissue
sections 3-µm in thickness from formalin-fixed, paraffin-embedded (FFPE) tissue was deparaffinized
and rehydrated using a xylene and alcohol solution. IHC was performed using a Ventana Discovery XT
automated stainer (Ventana Medical System, Tucson, AZ, USA). Cell Conditioning 1 buffer (CC1; citrate
buffer pH 6.0, Ventana Medical System) was used for antigen retrieval. Appropriate positive and negative
controls were included. The positive controls are used as manufacturer’s suggestion (ATX; human tonsil
tissue, LPA1; human colon tissue, LPA2; Breast cancer tissue, LPA3; Human prostate carcinoma).
Table 1. Source, clone, and dilution of antibodies.
Antibody Company Clone Dilution
ATX-LPA pathway-related proteins
ATX Abcam, Cambridge, UK Polyclonal 1:1000
LPA1 Abcam, Cambridge, UK EPR9710 1:100
LPA2 Abcam, Cambridge, UK Polyclonal 1:100
LPA3 Abcam, Cambridge, UK Polyclonal 1:250
Molecular subtype-related proteins
Estrogen receptor (ER) Thermo Scientific, San Diego, CA, USA SP1 1:100
Progesterone receptor (PR) DAKO, Glostrup, Denmark PgR 1:50
Human epidermal growth factor receptor-2 (HER2) DAKO, Glostrup, Denmark Polyclonal 1:1500
Ki-67 Abcam, Cambridge, UK SP6 1:100
ATX, autotaxin; LPA, lysophosphatidate.
Int. J. Mol. Sci. 2019, 20, 2102 3 of 16
2.4. Interpretation of Immunohistochemical Staining
All immunohistochemical markers were accessed by light microscopy. A cut-off value of at least
1% positively stained nuclei was used to define estrogen receptor (ER) and progesterone receptor (PR)
positivity [17]. Human epidermal growth factor receptor (HER)2 staining was analyzed according to
the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines
using the following categories: 0 = no immunostaining; 1+ = weak incomplete membranous staining,
less than 10% of tumor cells; 2+ = complete membranous staining, either uniform or weak in at least
10% of tumor cells; and 3+ = uniform intense membranous staining in at least 30% of tumor cells [18].
HER2 immunostaining was considered positive when strong (3+) membranous staining was observed,
whereas cases with 0 to 1+ were regarded as negative. Cases showing 2+ HER2 expression were
evaluated for HER2 amplification using fluorescent in situ hybridization (FISH). Ki-67 labeling index
(LI) was defined as the percentage of positive nuclear stained tumor cells.
IHC for ATX-LPA signaling-related proteins was evaluated in a semi-quantitative manner [19].
Tumor and stromal cell staining were assessed as follows: 0 = negative or weak immunostaining in
<1% of the tumor/stroma, 1 = focal expression in 1–10% of tumor/stroma, 2 = positive in 11%–50% of
tumor/stroma, and 3 = positive in 51%–100% of tumor/stroma. The whole tumor area was evaluated,
and a score of 0, 1 was assigned as negative and scores of 2 and higher were assigned as positive.
2.5. Western Blotting
Deparaffinization and protein extraction of FFPE tissue was carried out using Qproteome FFPE
Tissue Kit (Qiagen, Hilden, Germany; #1042481) following manufacturer’s instructions. Extracted
proteins were determined by Bradford assay (BIO-RAD, CA, USA; #5000205). Quantified proteins were
mixed with 5 × SDS-PAGE loading buffer (Biosesang, Seongnam, Korea; S2002) in concentration of
2 µg/µL and boiled at 95 ◦C for 5 min. Equal quantities of protein were separated to SDS-PAGE gel and
transferred to nitrocellulose membranes (BIO-RAD; #1704158). Membranes were blocked by incubation
in 5% skim milk in Tris-buffered saline (TBS) with 0.1% Tween-20 and probed with antibody against
ATX (1:1000; Abcam, Cambridge, UK; ab140915), LPA1(1:2000; Abcam; ab166903), and LPA2(1:1000;
Abcam; ab38322) diluted in 1% BSA in TBS, 0.1% Tween 20, and 0.02% NaN3. The membranes were
washed and then incubated with secondary antibodies (HRP conjugated anti-mouse IgG, or anti-rabbit
IgG) (1:20,000; Santa Cruz, TX, USA) for 1 h at room temperature. The bands were visualized using
WesternBright ECL (Advansata, CA, USA; K-12045-D50) after washing the membrane and exposed to
X-ray film.
2.6. Tumor Phenotype Classification
We classified the breast cancer phenotypes according to the immunohistochemistry results for ER,
PR, HER2, and Ki-67, and the silver in situ hybridization results for HER2, as follows [20]:
* luminal A type: ER- or PR-positive, or both, HER2-negative
* luminal B type: (HER2-negative) ER- or PR-positive, or both, HER2-negative, and Ki-67 LI ≥14%;
(HER2-positive) ER- or PR-positive, or both, and HER2overexpressed or amplified, or both
* HER2 type: HER2-overexpressed or amplified, or both, regardless of ER and/or PR status
* Triple Negative Breast Cancer (TNBC) type: ER-, PR-, and HER2-negative
3. Statistical Analysis
Data were analyzed using SPSS for Windows, Version 23.0 (SPSS Inc., Chicago, IL, USA).
For determination of statistical significance, the Student’s t and Person chi-square tests were used
for continuous and categorical variables, respectively. In the case of analyzing data with multiple
comparisons, a corrected p-value with the application of the Bonferroni multiple comparison procedure
was used. Correlation analysis was evaluated using the Pearson correlation coefficient (r). Statistical
significance was set to p < 0.05. Kaplan–Meier survival curves and log-rank statistics were employed to
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evaluate time to tumor recurrence and overall survival. Multivariate regression analysis was performed
using the Cox proportional hazards model.
4. Results
4.1. Characteristics of Patients According to Breast Cancer Stroma Type
There was a total of 137 (29.4%) breast cancer tissues containing adipose stroma and 329 (70.6%)
with non-adipose stroma, with non-adipose stroma subdivided into inflammatory stroma (n = 81,
24.6%), and fibrous stroma (n = 248, 53.2%). Histologic grade, ER status, PR status, HER2 status,
and molecular subtype were significantly different between groups (p < 0.001). Breast cancer with
inflammatory stroma had a higher histologic grade, and frequently showed ER negativity, PR negativity,
HER2 positivity, and non-luminal A type (Table 2).
Table 2. Clinicopathologic characteristics of patients according to breast cancer stroma type.
Parameter Total(n = 466) (%)
Adipose Stroma
(n = 137) (%)
Non-Adipose Stroma
(n = 329) (%)
p-Value * p-Value
Inflammatory
(n = 81) (%)
Fibrous
(n = 248) (%)
Age (years) 0.896 0.612
≤50 287 (61.6) 85 (62.0) 46 (56.8) 156 (62.6)
>50 179 (38.4) 52 (38.0) 35 (43.2) 92 (37.1)
Histologic grade 0.045 <0.001
I/II 341 (73.2) 109 (79.6) 43 (53.1) 189 (76.2)
III 125 (26.8) 28 (20.4) 38 (46.9) 59 (23.8)
Tumor stage 0.910 0.948
T1 257 (55.2) 75 (54.7) 46 (56.8) 136 (54.8)
T2/T3 209 (44.8) 62 (45.3) 35 (43.2) 112 (45.2)
Nodal metastasis 0.936 0.537
Absent 281 (60.3) 83 (60.6) 53 (65.4) 145 (58.5)
Present 185 (39.7) 54 (39.4) 28 (34.6) 103 (41.5)
ER <0.001 <0.001
Negative 115 (24.7) 19 (13.9) 39 (48.1) 57 (23.0)
Positive 351 (75.3) 118 (86.1) 42 (51.9) 191 (77.0)
PR 0.002 <0.001
Negative 141 (30.5) 28 (20.4) 39 (48.1) 75 (30.2)
Positive 324 (65.4) 109 (79.6) 42 (51.9) 173 (69.8)
HER2 status 0.157 <0.001
Negative 387 (83.0) 119 (86.9) 55 (67.9) 213 (85.9)
Positive 79 (17.0) 18 (13.1) 26 (32.1) 35 (14.1)
Molecular subtype <0.001 <0.001
Luminal A 270 (57.9) 107 (78.1) 23 (28.4) 140 (56.5)
Luminal B 105 (22.5) 14 (10.2) 28 (34.6) 63 (25.4)
HER2 22 (4.7) 2 (1.5) 9 (11.1) 11 (4.4)
Triple negative breast
cancer (TNBC) 69 (14.8) 14 (10.2) 21 (25.9) 34 (13.7)
* Comparison of adipose stroma and non-adipose stroma; Bold, p-value < 0.05.
4.2. Expression of ATX-LPA Signaling-Related Proteins according to Breast Cancer Stroma Type
ATX, LPA1, and LPA3 were expressed in tumor cells as well as stromal cells, whereas LPA2
was only expressed in tumor cells. LPA2 in tumor cells and LPA3 in stromal cells were differentially
expressed according to the type of breast cancer stroma. LPA2 was highly expressed in breast cancer
with adipose stroma. Stromal LPA3 was highly expressed in breast cancer with adipose stroma and
inflammatory stroma. Immune cells, such as macrophages, were stromal cells that were positive for
LPA3 (Table 3, Supplementary Figure S1 and Figure 1). In Western blot analysis, the ATX and LPA1
expressions had no significant differences among stroma types nor cancers around them. However,
level of LPA2 of tumor around adipose stroma was much higher than the other tumors surrounded by
inflammatory or fibrous stroma (Figure 2).
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Figure 1. Expression of ATX-LPA signaling-related proteins according to breast cancer stroma type 
in immunohistochemical stain. High expression of LPA2 in cancer cells is observed in the breast 
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breast cancer with adipose stroma and breast cancer with inflammatory stroma (*). LPA3 positive 
stromal cells are immune cells like macrophages. H&E, hematoxylin and eosin. Scale bar represents 
200 μm. 
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Table 3. Expression of ATX-LPA signaling-related proteins according to breast cancer stroma type.
Parameter Total(n = 466) (%)
Adipose Stroma
(n = 137) (%)
Non-Adipose Stroma
(n = 329) (%)
p-Value * p-Value
Inflammatory
(n = 81) (%)
Fibrous
(n = 248) (%)
ATX 0.086 0.062
Negative 243 (52.1) 63 (46.0) 38 (46.9) 142 (57.3)
Positive 223 (47.9) 74 (54.0) 43 (53.1) 106 (42.7)
ATX (S) 0.357 0.511
Negative 390 (83.7) 118 (86.1) 69 (85.2) 203 (81.9)
Positive 76 (16.3) 19 (13.9) 12 (14.8) 45 (18.1)
LPA1 0.514 0.363
Negative 249 (53.4) 70 (51.1) 49 (60.5) 130 (52.4)
Positive 217 (46.6) 67 (48.9) 32 (39.5) 118 (47.6)
LPA1 (S) 0.854 0.951
Negative 382 (82.0) 113 (82.5) 67 (82.7) 202 (81.5)
Positive 84 (18.0) 24 (17.5) 14 (17.3) 46 (18.5)
LPA2 <0.001 <0.001
Negative 409 (87.8) 85 (62.0) 80 (98.8) 244 (98.4)
Positive 57 (12.2) 52 (38.0) 1 (1.2) 4 (1.6)
LPA 3 0.451 0.121
Negative 436 (93.6) 130 (94.9) 79 (97.5) 227 (91.5)
Positive 30 (6.4) 7 (5.1) 2 (2.5) 21 (8.5)
LPA 3 (S) 0.027 <0.001
Negative 304 (65.2) 79 (57.7) 34 (42.0) 191 (77.0)
Positive 162 (34.8) 58 (42.3) 47 (58.0) 57 (23.0)
* Comparison of adipose stroma and non-adipose stroma. S, stromal; Bold, p-value < 0.05.Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  7 of 18 
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Figure 2. Expression of ATX-LPA signaling-related proteins according to breast cancer stroma type in
Western blot. ATX and LPA1 expressions had no significant differences among stroma types or cancers
around them. However, level of LPA2 of tumor around adipose stroma was much higher than the other
tumors surrounded by inflammatory or fibrous stroma. T, tumor; S, stroma.
4.3. Correlation of the Expression of ATX-LPA Signaling-Related Proteins
Positive correlations were found in ATX-stromal ATX (r = 0.348, p < 0.001), ATX-LPA1 (r = 0.367,
p < 0.001), ATX-stromal LPA1 (r = 0.125, p = 0.007), ATX-LPA2 (r = 0.159, p = 0.001), stromal ATX-LPA1
(r = 0.141, p = 0.002), stromal ATX-stromal LPA1 (r = 0.352, p < 0.001), stromal ATX-stromal LPA3
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(r = 0.121, p = 0.009), LPA1-stromal LPA1(r = 0.273, p < 0.001), LPA1-LPA2 (r = 0.221, p < 0.001),
LPA1-stromal LPA3 (r = 0.216, p < 0.001), and stromal LPA1-stromal LPA3 (r = 0.291, p < 0.001) (Table 4).
Table 4. Correlation among the expression of ATX-LPA signaling-related proteins.
Parameters ATX (S) LPA1 LPA1 (S) LPA2 LPA3 LPA3 (S)
ATX
r-value 0.348 0.367 0.125 0.159 −0.036 0.081
p-value <0.001 <0.001 0.007 0.001 0.443 0.082
ATX (S)
r-value 0.141 0.352 0.090 −0.023 0.121
p-value 0.002 <0.001 0.051 0.616 0.009
LPA1
r-value 0.273 0.221 0.086 0.216
p-value <0.001 <0.001 0.065 <0.001
LPA1 (S)
r-value 0.085 −0.017 0.291
p-value 0.066 0.715 <0.001
LPA2
r value 0.008 0.079
p-value 0.871 0.089
LPA3
r-value −0.064
p-value 0.165
Bold, p-value < 0.05.
4.4. Correlation between the Expression of ATX-LPA Signaling-Related Proteins and Macrophages in
Adipose Stroma
We have previously reported infiltrating macrophages in adipose stroma of breast cancer
recognized by CD68 and CD163 IHC [21], and the results of the previous study were used to analyze
this relationship with the expression of ATX-LPA signaling-related proteins. CD68-positive crown-like
structure (CLS) was correlated with a higher rate of stromal LPA1 positivity (p = 0.017) and stromal
LPA3 positivity (p = 0.004). CD163-positive CLS was correlated with higher stromal ATX positivity
(p = 0.010) and stromal LPA3 positivity (p = 0.009) (Table 5 and Figure 2). Stromal ATX positivity was
correlated with the number of CD163-positive macrophages infiltrating the adipose stroma (p = 0.003).
Stromal LPA3 positivity was correlated with number of both CD68- and CD163-positive macrophages
(p < 0.001, Table 6 and Figure 3).
Table 5. Expression of ATX-LPA signaling-related proteins according to CD68- and CD163-positive
crown-like structure (CLS) status in adipose stroma.
Parameter
CD68-Positive CLS CD163-Positive CLS
Absent
(n = 114) (%)
Present
(n = 23) (%) p-Value
Absent
(n = 119) (%)
Present
(n = 18) (%) p-Value
ATX 0.791 0.888
Negative 53 (46.5) 10 (43.5) 55 (46.2) 8 (44.4)
Positive 61 (53.5) 13 (56.5) 64 (53.8) 10 (55.6)
ATX (S) 0.063 0.010
Negative 101 (88.6) 17 (73.9) 106 (89.1) 12 (66.7)
Positive 13 (11.4) 6 (26.1) 13 (10.9) 6 (33.3)
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Table 5. Cont.
Parameter
CD68-Positive CLS CD163-Positive CLS
Absent
(n = 114) (%)
Present
(n = 23) (%) p-Value
Absent
(n = 119) (%)
Present
(n = 18) (%) p-Value
LPA 1 0.910 0.545
Negative 58 (50.9) 12 (52.2) 62 (52.1) 8 (44.4)
Positive 56 (49.1) 11 (47.8) 57 (47.9) 10 (55.6)
LPA 1 (S) 0.017 0.219
Negative 98 (86.0) 15 (65.2) 100 (84.0) 13 (72.2)
Positive 16 (14.0) 8 (34.8) 19 (16.0) 5 (27.8)
LPA 2 0.731 0.665
Negative 70 (61.4) 15 (65.2) 73 (61.3) 12 (66.7)
Positive 44 (38.6) 8 (34.8) 46 (38.7) 6 (33.3)
LPA 3 0.222 0.291
Negative 107 (93.9) 23 (100.0) 112 (94.1) 18 (100.0)
Positive 7 (6.1) 0 (0.0) 7 (5.9) 0 (0.0)
LPA 3 (S) 0.004 0.009
Negative 72 (63.2) 7 (30.4) 74 (62.2) 5 (27.8)
Positive 42 (36.8) 16 (69.6) 45 (37.8) 13 (72.2)
Bold, p-value < 0.05.
Table 6. The number of CD68- and CD163-positive macrophages in adipocytes according to the
expression of ATX-LPA signaling-related proteins.
Parameter
The Number of CD68-Positive
Macrophages in Adipocyte
The Number of CD163-Positive
Macrophages in Adipocyte
Median (Range) p-Value Median (Range) p-Value
ATX 0.234 0.526
Negative 5 (0–42) 13 (0–79)
Positive 1.5 (0–41) 12 (0–62)
ATX (S) 0.179 0.003
Negative 2 (0–42) 12 (0–62)
Positive 8 (0–32) 20 (0–79)
LPA1 0.586 0.179
Negative 2 (0–42) 10 (0–79)
Positive 4 (0–41) 13 (0–62)
LPA1 (S) 0.066 0.094
Negative 2 (0–42) 12 (0–79)
Positive 7 (0–37) 14 (0–52)
LPA 2 0.395 0.943
Negative 3 (0–42) 12 (0–79)
Positive 3 (0–36) 12.5 (0–57)
LPA 3 0.350 0.576
Negative 3 (0–42) 12 (0–79)
Positive 3 (0–9) 12 (0–20)
LPA 3 (S) <0.001 <0.001
Negative 0 (0–41) 8 (0–79)
Positive 8 (0–42) 16.5 (0–62)
Bold, p-value < 0.05.
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Figure 3. Correlation between the expression of ATX-LPA signaling-related proteins and macrophages
in adipose stroma. Increased ATX expression in stromal cells is associated with increased number of
CD163-positive macrophages (*). Increased LPA3 expression in stromal cells is associated with high
numbers of both CD68- and CD163-positive macrophages (*). Note CD68 and CD163-positive CLS
(inlet). Scale bar represents 200 µm.
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4.5. ATX-LPA Signaling-Related Proteins and Clinicopathologic Parameters
LPA1 positivity was associated with higher histologic grade (p < 0.001) and stromal LPA3 positivity
was associated with higher histologic grade (p < 0.001), ER negativity (p < 0.001), and non-luminal
A type (p = 0.001) (Figure 4 and Supplementary Table S1). In further subgroup analysis for breast
cancer with adipose stroma and non-adipose stroma, stromal LPA3 positivity showed significant
association with higher histologic grade in adipose stroma group (p < 0.001), and higher histologic
grade (p < 0.001), ER negativity (p < 0.001), and non-luminal A type (p = 0.001) in non-adipose stroma
group (Supplementary Figure S2).
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Figure 4. Correlation between clinicopathologic parameters and the expression of ATX-LPA
signaling-related proteins. LPA1 positivity is associated with higher histologic grade (p < 0.001),
and stromal LPA3 positivity is associated with higher histologic grade (p < 0.001), ER negativity
(p < 0.001), and non-luminal A type (p = 0.001). HG, histologic grade.
4.6. Impact of the Expression of ATX-LPA Signaling-Related Proteins on Patient Prognosis
On univariate analysis, expression of ATX-LPA signaling-related proteins and patient prognosis
showed no ignificant association (Table 7). H wever, univariate analysis within subgroups showed
that shorter disease-free survival was associated with LPA positivity (p = 0.005) and stromal LPA3
negativity (p = 0.015) in breast cancer with adipose stoma and ER negative cases, and LPA3 positivity
(p = 0.007) was associated with shorter overall survival (Figure 3). LPA3 positivity (p = 0.008) was
associated with shorter overall survival in breast cancer with adipose stroma and PR negative cases
(Figure 5).
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Figure 5. Disease-free survival and overall survival according to LPA3 expression in breast cancer with
adipose stroma. In breast cancer with adipose stroma and ER-negative breast cancer, LPA3 positivity (a)
and stromal LPA3 negativity (b) are associated with shorter disease-free survival, and LPA3 positivity
is associated with shorter overall survival (OS) (c). LPA3 positivity is assoc ated with shorter OS in
brea t cancer with adipose st oma nd PR-negative breast cancer (d). Green, censored LPA3(S) positive
patients; blue, censored LPA3 negative patients
Table 7. Univariate analysis of the impact of expression of ATX-LPA signaling-related proteins in breast
cancers on disease-free survival and overall survival by the log-rank test.
Par meter
Number of
Patients/Recurrence/Death
Disease-Free Survival Overall Survival
Mean Survival
(95% CI) Months p-Value
Mean Survival
(95% CI) Months p-Value
ATX 0.842 0.649
Negative 243/13/22 119 (117–122) 117 (114–120)
Positive 223/13/18 133 (129–136) 130 (125–135)
ATX (S) 0.093 0.868
Negative 390/25/34 132 (129–134) 129 (126–133)
Positive 76/1/6 107 (106–108) 104 (101–107)
LPA1 0.115 0.888
Negative 249/18/22 131 (128–135) 129 (125–134)
Positive 217/8/18 113 (111–115) 110 (107–112)
LPA1 (S) 0.152 0.544
Negative 382/24/34 132 (129–135) 129 (125–133)
Positive 84/2/6 113 (111–115) 111 (108–114)
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Table 7. Cont.
Parameter
Number of
Patients/Recurrence/Death
Disease-Free Survival Overall Survival
Mean Survival
(95% CI) Months p-Value
Mean Survival
(95% CI) Months p-Value
LPA 2 0.528 0.413
Negative 409/22/37 133 (131–135) 129 (126–133)
Positive 57/4/3 110 (105–115) 112 (108–116)
LPA 3 0.607 0.770
Negative 436/25/38 133 (130–135) 130 (127–133)
Positive 30/1/2 112 (105–119) 109 (101–118)
LPA 3 (S) 0.661 0.504
Negative 304/16/28 133 (130–136) 130 (127–133)
Positive 162/10/12 112 (109–115) 111 (108–114)
CI, confidence interval.
5. Discussion
We investigated the expression of ATX-LPA signaling-related proteins in breast cancer with
adipose stroma. Compared with breast cancer with non-adipose stroma, breast cancer with adipose
stroma had higher LPA2 expression of tumor cells. Previous studies have shown higher expression
of ATX and LPA1, 2, and 3 in breast cancer compared with normal breast tissue [22–25]. In human
breast cancer, tumor cells show higher expression of LPA2 than LPA1 and LPA3 in postmenopausal
breast cancer tissue [26]. However, previous studies have lacked information regarding ATX-LPA
signaling-related protein expression according to the stromal type. Higher LPA2 expression in tumor
cells of breast cancer with adipose stroma may be affected by interactions between cancer cells and
cancer-associated adipocytes (CAAs). Various cross-talk and interactions are present between breast
cancer cells, stromal cells, and adipocytes [27]. Between adipocytes, one of the stromal components of
breast cancer, these interactions affect tumor biology [28]. Increased secretion of various adipokines
by CAAs in close proximity to tumor cells has an effect on tumor cells. Conversely, cytokines and
growth factors secreted from tumor cells also influence adipocytes in the vicinity, which is a reciprocal
interaction between breast cancer cells and adjacent adipocytes [29]. Hence, CAAs may play a role
in the high expression of LPA2 in breast cancer cells, which requires further study. A previous
study reported that LPA2 of breast cancer cells regulates HIF-1α expression and is involved in cell
proliferation, migration, and invasion [30]. LPA2 expression was associated with nodal metastasis and
higher stage [30]. Therefore, higher expression of LPA2 in tumor cells of breast cancer with adipose
stroma may have an effect on breast cancer biology.
In the present study, stromal LPA3 was highly expressed in breast cancer with adipose stroma and
breast cancer with inflammatory stroma, and was particularly positive in the immune cells, such as
macrophages. Previous studies have also recognized that expression of ATX-LPA signaling-related
proteins was found in stromal cells, mostly fibroblasts [22,24,25,31]. We also identified protein
expression in fibroblasts, as well as in immune cells. The ATX-LPA receptor axis affects breast
cancer-related inflammation; in MMTV-LPR transgenic mice, expression of ATX, LPA1, LPA2, and LPA3
for mammary cancer induction was associated with inflammation in mammary tissue, even before
tumor development [32]. ATX secreted from tumor and stromal cells induces LPA, which enhances
NF-κB expression via the PKC or AKT pathway, induces ATF-2 via the Rho-CDC42-p38 MAPK pathway,
and activates STAT3 and STAT5, which induces the synthesis of inflammatory cytokines, chemokines,
and COX-2 [32–35]. Thus, the ATX-LPA receptor axis generates inflammatory factors and facilitates an
inflammatory tumor microenvironment.
We observed LPA3 expression in immune cells in breast cancer with adipose stroma or inflammatory
stroma. Stromal LPA3 positivity was associated with CD68- and CD163-positive CLS, and correlated
with CD68- and CD163-positive macrophages infiltrating in adipose tissue. As macrophages were
frequently positive for LPA3, LPA3 may be associated with tumor-associated macrophages. Among the
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tumor microenvironment of breast cancer, tumor-associated macrophages (TAMs) are a predominant
component of tumor mass, and a subset of breast cancer comprises more than 50% TAMs [36]. Further
study on LPA3 positive TAMs is required, as TAMs in breast cancer are involved in various processes,
such as tumor progression, metastasis, immune alteration, drug resistance, and cancer stem cells [37].
The present study reports an association between LPA3 positivity and poor prognosis in ER- and
PR-negative breast cancer with adipose stroma. In a previous study, LPA3 expression in breast cancer
was associated with high tumor grade, HER2 positivity, and lymph node metastasis [24]. Moreover,
LPA3 transgenic mice showed high rate of metastasis [32], suggesting that LPA is an indicator of poor
prognosis in breast cancer, which needs to be validated in a future study.
The ATX-LPA axis can be a therapeutic target of breast cancer. Since tumor and stromal cells in
breast cancer express ATX-LPA signaling-related proteins, inhibition of the ATX-LPA axis could have
a dual effect. Ki16245, a non-lipid competitive inhibitor of LPA and LPA3, reduces bone metastasis
of breast cancer in a mouse model [10]. Debio0719, an R-stereoisomer of Ki16425, reduced lung and
bone metastasis [38] and liver and lung metastasis [39] in a mouse model. BrP-LPA, a dual ATX
and pan-LPAR inhibitor, inhibited migration and invasion of breast cancer cell lines and suppressed
primary tumor and angiogenesis in a mouse xenograft study [40]. ONO-843050, an ATX inhibitor,
reduced tumor growth of breast cancer in a mouse model, and had a subsequent decrease in lung
metastasis by up to 60% [41]. Therefore, further study on the blockade of the ATX-LPA axis in breast
cancer with adipose stroma and inflammatory stroma is required.
In conclusion, LPA2 and stromal LPA3 are highly expressed in breast cancer with adipose stroma.
Among them, stromal LPA3 expression of breast cancer with adipose stroma is associated with
macrophage infiltration.
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